Year-end Report 2009 Tripep AB (publ)

Year-end Report 2009 Tripep AB (publ)

	Research and development costs amounted to SEK 6.4 (17.1) m
	The loss after tax was SEK -11.6 (-24.9) m
	Earnings per share were SEK -0.27 (-1.77)
	Net sales SEK 0.4 (3.8) m
	The company has carried out two private placements raising SEK 6 m before
transaction costs through the placements during the summer 2009, and in December
2009 a rights offering which was fully subscribed. Through the rights offering
Tripep received 17.8 MSEK before transaction costs
	The ChronVac-C® study has been finalized and showed that the therapeutic
vaccine is safe and gave positive clinical data. The Swedish Medical Product's
Agency and the ethical committees in December gave their approvals for giving
three of the patients in the ChronVac-C® study a 5th dose. This dose is given
approximately six to 12 months after the 4th vaccination in order to study
possible positive effects of a so called booster-dose given after a longer time
frame. Four patients who after completing the ChronVac-C® study have started
treatment according to standard of care, i.e. interferon in combination with
ribavirin have responded with an unusually rapid reduction of virus in the
blood. This indicates a role for ChronVac-C® in combination therapy 
	The multi-center study on ChronSeal® is ongoing in Sweden and Norway. In an
interim analysis of the treatment effect it was concluded that the group of
patients randomized for placebo treatment with the new antibacterial formulation
without HGF still was too small for allowing statistical analysis
	Tripep has out licensed the RAS® technology to Opsonic Therapeutics
	Tripep has applied for a patent for a new type of injection-needle for DNA
vaccination in man. The needle is intended for use with commercially available
syringes and has in animal experiments been shown to increase the effect of DNA
vaccination as compared to normal injection needles

Events after the end of the reporting period
	Follow up of ChronVac-C® study with a 5th dose commenced


For more information, please contact:

Anders Vahlne, CEO and Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, 
E-mail: anders.vahlne@ki.se


Tripep develops the therapeutic DNA-vaccines ChronVac-C® and ChronVac-B drugs
against chronic hepatitis C virus and hepatitis B-virus infections, i.e. chronic
infections with jaundice causing viruses which can lead to liver cirrhosis and
liver cancer. Tripep has also developed and further develops a patent pending
new type of injection needle for a more effective uptake of DNA vaccines. Tripep
also have part ownership in the wound healing therapy ChronSeal®, and in the new
platform technology RAS®. The Tripep share is admitted to trade on First North.
Remium AB is Certified Adviser for Tripep AB. For more information, please
visit: www.tripep.se

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.